Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
AssigneeVoltarra Pharmaceuticals, Inc.
InventorKetan Desai
Life of this patent
Estimating the term…
Abstract
A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.
Claims17
A method of treating or preventing osteoarthritis, the method comprising administering a combination of a steroid and a compound of the formula:
- wherein R1 is a 5-membered heteroaryl radical which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, wherein the term “lower” means from 1 to 7 carbon atoms, lower alkoxy is C1-4 alkoxy, di-lower alkylamino is di-C1-4 alkylamino, lower alkylthio is C1-4 alkylthio, halogen is fluorine, chlorine or bromine. to a patient in need of treatment or prevention thereof.
A composition comprising methyl prednisolone and Zoledronic Acid in a pharmaceutically acceptable solution for intravenous administration.
A method for treating osteoarthritis in a joint, comprising administering a combination of a steroid and Zoledronic Acid directly into the joint.
Dependencies are inferred from the claim text.